Upcoming event

Indocyanine green guidance during 3D augmented reality robot assisted partial nephrectomy: A step towards the “automatic” overlapping

New technologies in robot-assisted kidney transplantation: Improving surgical performances, expanding the indication

Robot-assisted partial nephrectomy with 3D preoperative surgical planning: Video presentation of the florentine experience

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

European Urology, Volume 79, Issue 4, April 2021, Pages 468-477

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial

Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

Essential research priorities in renal cancer: a modified delphi consensus statement

European Urology Focus, September 2021

Next